Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
940 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05572515 | A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma(MajesTEC-9) | active not recruiting | Phase 3 | 614 | Janssen Research & Development, LLCINDUSTRY | 24 | Apr 13, 2026 | clinicaltrials |
| NCT04562389 | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis(SENTRY) | active not recruiting | Phase 3 | 353 | Karyopharm Therapeutics Inc |
| 20 |
| Apr 9, 2026 |
| clinicaltrials |
| NCT06064877 | A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma(FIERCE-HN) | recruiting | Phase 3 | 410 | AVEO Pharmaceuticals, Inc.INDUSTRY | 18 | Apr 9, 2026 | clinicaltrials |
| NCT04102020 | A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy(VIALE-M) | completed | Phase 3 | 112 | AbbVieINDUSTRY | 19 | Apr 8, 2026 | clinicaltrials |
| NCT06508658 | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(EPCORE DLBCL-4) | active not recruiting | Phase 3 | 379 | GenmabINDUSTRY | 28 | Apr 8, 2026 | clinicaltrials |
| NCT05382299 | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer(ASCENT-03) | active not recruiting | Phase 3 | 623 | Gilead SciencesINDUSTRY | 30 | Apr 6, 2026 | clinicaltrials |
| NCT06522737 | A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype(TERZO) | recruiting | Phase 3 | 124 | SecuraBioINDUSTRY | 10 | Apr 6, 2026 | clinicaltrials |
| NCT04256421 | A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer(SKYSCRAPER-02) | completed | Phase 3 | 490 | Hoffmann-La RocheINDUSTRY | 23 | Apr 3, 2026 | clinicaltrials |
| NCT04975997 | Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)(EXCALIBER-RRMM) | active not recruiting | Phase 3 | 939 | CelgeneINDUSTRY | 31 | Apr 3, 2026 | clinicaltrials |
| NCT05514054 | A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer(EMBER-4) | active not recruiting | Phase 3 | 8,000 | Eli Lilly and CompanyINDUSTRY | 31 | Apr 2, 2026 | clinicaltrials |
| NCT04498117 | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery(FLORA-5) | active not recruiting | Phase 3 | 615 | CanariaBio Inc.INDUSTRY | 14 | Apr 1, 2026 | clinicaltrials |
| NCT04824092 | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients(frontMIND) | active not recruiting | Phase 3 | 899 | Incyte CorporationINDUSTRY | 29 | Apr 1, 2026 | clinicaltrials |
| NCT02684708 | Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents | completed | Phase 3 | 2,921 | University of GiessenOTHER | 19 | Mar 31, 2026 | clinicaltrials |
| NCT06932562 | A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant | recruiting | Phase 3 | 1,000 | European Myeloma Network B.V.NETWORK | 18 | Mar 25, 2026 | clinicaltrials |
| NCT04211337 | A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer(LIBRETTO-531) | active not recruiting | Phase 3 | 291 | Loxo Oncology, Inc.INDUSTRY | 20 | Mar 19, 2026 | clinicaltrials |
| NCT02973789 | Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) | completed | Phase 3 | 291 | NovoCure GmbHINDUSTRY | 18 | Mar 18, 2026 | clinicaltrials |
| NCT05654623 | A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer(VERITAC-2) | active not recruiting | Phase 3 | 624 | PfizerINDUSTRY | 31 | Mar 18, 2026 | clinicaltrials |
| NCT02947347 | Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma | completed | Phase 3 | 445 | Pharmacyclics LLC.INDUSTRY | 19 | Mar 17, 2026 | clinicaltrials |
| NCT05257083 | A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma(CARTITUDE-6) | active not recruiting | Phase 3 | 759 | Stichting European Myeloma NetworkNETWORK | 16 | Mar 17, 2026 | clinicaltrials |
| NCT07476729 | International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) | not yet recruiting | Phase 3 | 750 | Charite University, Berlin, GermanyOTHER | 20 | Mar 17, 2026 | clinicaltrials |
| NCT03142334 | Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) | completed | Phase 3 | 994 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Mar 10, 2026 | clinicaltrials |
| NCT03336333 | A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL(SEQUOIA) | active not recruiting | Phase 3 | 590 | BeiGeneINDUSTRY | 15 | Mar 9, 2026 | clinicaltrials |
| NCT03036098 | Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer(CheckMate901) | active not recruiting | Phase 3 | 1,314 | Bristol-Myers SquibbINDUSTRY | 30 | Mar 6, 2026 | clinicaltrials |
| NCT04819100 | A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)(LIBRETTO-432) | active not recruiting | Phase 3 | 152 | Eli Lilly and CompanyINDUSTRY | 32 | Mar 4, 2026 | clinicaltrials |
| NCT05218499 | Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma | completed | Phase 2 / Phase 3 | 400 | Boehringer IngelheimINDUSTRY | 22 | Mar 2, 2026 | clinicaltrials |
| NCT01602380 | A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.(FALCON) | completed | Phase 3 | 462 | AstraZenecaINDUSTRY | 20 | Feb 27, 2026 | clinicaltrials |
| NCT01712490 | A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma | completed | Phase 3 | 1,334 | TakedaINDUSTRY | 21 | Feb 27, 2026 | clinicaltrials |
| NCT01909453 | Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma(COLUMBUS) | completed | Phase 3 | 921 | PfizerINDUSTRY | 29 | Feb 27, 2026 | clinicaltrials |
| NCT03523585 | DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] | completed | Phase 3 | 608 | Daiichi SankyoINDUSTRY | 15 | Feb 27, 2026 | clinicaltrials |
| NCT03675737 | Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) | completed | Phase 3 | 1,579 | Merck Sharp & Dohme LLCINDUSTRY | 33 | Feb 27, 2026 | clinicaltrials |
| NCT06346067 | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | active not recruiting | Phase 3 | 78 | Erasca, Inc.INDUSTRY | 9 | Feb 27, 2026 | clinicaltrials |
| NCT06112314 | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)(PRISM-MEL-301) | recruiting | Phase 3 | 680 | Immunocore LtdINDUSTRY | 26 | Feb 25, 2026 | clinicaltrials |
| NCT04697628 | Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer(innovaTV 301) | completed | Phase 3 | 502 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 25 | Feb 24, 2026 | clinicaltrials |
| NCT00699751 | A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases(ALSYMPCA) | completed | Phase 3 | 921 | BayerINDUSTRY | 19 | Feb 23, 2026 | clinicaltrials |
| NCT02811861 | Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma(CLEAR) | active not recruiting | Phase 3 | 1,069 | Eisai Inc.INDUSTRY | 20 | Feb 23, 2026 | clinicaltrials |
| NCT05171049 | A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE(ASTER) | terminated | Phase 3 | 1,150 | Anthos Therapeutics, Inc.INDUSTRY | 21 | Feb 23, 2026 | clinicaltrials |
| NCT04221945 | Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) | completed | Phase 3 | 1,060 | Merck Sharp & Dohme LLCINDUSTRY | 30 | Feb 20, 2026 | clinicaltrials |
| NCT05386550 | Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) | terminated | Phase 3 | 166 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 26 | Feb 19, 2026 | clinicaltrials |
| NCT03143153 | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin(CheckMate 648) | completed | Phase 3 | 970 | Bristol-Myers SquibbINDUSTRY | 27 | Feb 17, 2026 | clinicaltrials |
| NCT02000622 | Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.(OlympiAD) | completed | Phase 3 | 302 | AstraZenecaINDUSTRY | 19 | Feb 13, 2026 | clinicaltrials |
| NCT03710603 | Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma(Perseus) | active not recruiting | Phase 3 | 709 | Stichting European Myeloma NetworkNETWORK | 13 | Feb 10, 2026 | clinicaltrials |
| NCT05501886 | Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)(VIKTORIA-1) | active not recruiting | Phase 3 | 701 | Celcuity IncINDUSTRY | 23 | Feb 10, 2026 | clinicaltrials |
| NCT03275285 | Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients(IKEMA) | completed | Phase 3 | 302 | SanofiINDUSTRY | 16 | Feb 9, 2026 | clinicaltrials |
| NCT06097364 | A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma(OLYMPIA-2) | active not recruiting | Phase 3 | 733 | Regeneron PharmaceuticalsINDUSTRY | 17 | Feb 6, 2026 | clinicaltrials |
| NCT03673501 | A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib(INTRIGUE) | active not recruiting | Phase 3 | 453 | Deciphera Pharmaceuticals, LLCINDUSTRY | 22 | Feb 5, 2026 | clinicaltrials |
| NCT03040999 | Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412) | completed | Phase 3 | 804 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Feb 4, 2026 | clinicaltrials |
| NCT04965493 | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)(BRUIN CLL-322) | active not recruiting | Phase 3 | 600 | Loxo Oncology, Inc.INDUSTRY | 23 | Jan 29, 2026 | clinicaltrials |
| NCT05855200 | Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer | recruiting | Phase 3 | 892 | GlaxoSmithKlineINDUSTRY | 28 | Jan 23, 2026 | clinicaltrials |
| NCT04818671 | Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis(ADAPTSC+) | completed | Phase 3 | 184 | argenxINDUSTRY | 12 | Jan 22, 2026 | clinicaltrials |
| NCT03377491 | Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) | completed | Phase 3 | 571 | NovoCure Ltd.INDUSTRY | 20 | Jan 21, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials